Introduction
In 2001, van den Hoogen et al.
1 reported the discovery of human metapneumovirus (hMPV) from children with respiratory tract illness in The Netherlands. Since then, hMPV has been identified worldwide and co-circulation of different hMPV genotypes can occur in the same geographical area. 2, 3 So far, real-time PCR has been the preferred diagnostic method to detect hMPV.
The virus can cause prolonged and severe infections in the immunocompromised host, mainly in patients with hematological malignancies, after hematopoietic SCT (HSCT) and in lung transplant recipients. In 2002, a fatal case of lower respiratory tract infection was retrospectively demonstrated to be caused by hMPV in a child treated for ALL. 4 In the following year, Cane et al. 5 first reported a case of hMPV infection causing lethal pneumonia in an HSCT recipient. Since then, other series have reported the occurrence of hMPV infection in HSCT recipients. In a prospective 4-year study, Martino et al. 6 found a 2-year incidence of 5.2 and 3% in allogeneic and autologous HSCT recipients, respectively. Pneumonia caused by hMPV was seen more frequently in allogeneic than in autologous HSCT (44 versus 4%). Englund et al. 7 observed that 5 of 163 (3.0%) bronchoalveolar (BAL) lavage samples from HSCT recipients with lower respiratory tract disease were tested positive for hMPV. Peck et al.
8 observed a 5.8% cumulative incidence of hMPV in a prospective surveillance study in which patients were followed during four winter/spring seasons.
In the scenario of solid organ transplantation, hMPV has been associated with acute rejection and bronchiolitis obliterans syndrome in lung transplant recipients and can also cause severe disease. 9, 10 In the southern hemisphere, hMPV infection has been reported in healthy children, [11] [12] [13] but no data are available in HSCT recipients. Sa˜o Paulo is a city with a subtropical climate in the southeast region of Brazil. In general, respiratory viruses (RVs) circulate year round with moderate activity except by respiratory syncytial virus and influenza A and B, which peak in fall and winter, respectively.
14, 15 The present study was conducted to determine the frequency, seasonal distribution and genotypes of hMPV detected in HSCT recipients from Sa˜o Paulo, Brazil, during 3 consecutive years. 
Methods

Patients
Definitions
Upper respiratory infection was defined as the presence of coryza, pharyngitis, sinusitis and/or cough with or without fever and a clear chest computed tomography scan. Lower respiratory infection was defined as the presence of wheezing, hypoxia or pneumonia with a new tomographic infiltrate. As RV shedding can be prolonged in HSCT recipients, a different episode of RV infection was defined if another NW sample tested positive after at least two negative samples taken 7 days apart.
Clinical management
In symptomatic patients, NW samples were taken and a thorax computed tomography scan was performed. In the presence of pulmonary images, a BAL lavage was performed according to the clinician's discretion.
Infection control policies
The control of RV transmission in the HSCT unit included the following measures: (1) Influenza vaccination recommended for all HSCT recipients after the 6th month of transplantation, family members and health-care workers. (2) NW collected from all symptomatic patients to test for RVs using direct immunofluorescent assay and the patients kept under contact precautions until specific diagnosis. NW sampling and storage Clinical specimens were collected by instilling 3-6 ml of normal saline with a needleless syringe in the nostril of the patient as described by Englund et al., 16 kept on ice and processed within 3 h from sampling. Direct fluorescence assay (Imagen, Dako, Cambridgeshire, UK) was used to diagnose respiratory syncytial virus (RSV), influenza A and B, parainfluenza and adenovirus. The results of RV infections in HSCT recipients from 2001 to 2003 have been published elsewhere. 14, 15 Aliquots of the respiratory samples were stored in trizol at À80 1C until RNA extraction (trizol method; Invitrogen, Carlsbad, CA, USA).
Real-time PCR
The cDNA was amplified by the High-Capacity cDNA Arquive kit according to the manufacturer's instructions (Applied Biosystems Inc., Foster City, CA, USA). Metapneumovirus real-time PCR was developed at the Virology Laboratory of Institute of Tropical Medicine (Sa˜o Paulo, Brazil). A previous genomic comparison of several hMPV nucleocapsid sequences from different countries was accomplished using the software SeqMan (DNA-Star; ABI, Foster City, CA, USA). To overcome nucleotide mismatches among different groups of hMPV, two different forward primers-Care 1 and Care 2-were designed. Primers and MGB Taqman probes amplified a 74-bp fragment of the conserved nucleocapsid gene from the two hMPV groups (Care 1: GCACCAGACACACC CATAATCTT; Care 2: TCAGCACCAGACACACCTA TAATCTT; Care 3: TTGAGTGCATCACTTAGTA CACGGT; and Probe: 6 FAM-TTATGTGTAGGTG CCTTAATA-MGBFQ). The final protocol included a 25 ml reaction prepared by the addition of 5.0 ml of cDNA; 12.5 ml of Master Mix (2 Â ); 1.25 ml of primers Care 1 and Care 2 (10 mM); 2.5 ml of primer Care 3 (10 mM); 1.25 ml of probe (5 mM); and 1.25 ml of nuclease-free water (Invitrogen). DNA amplification was performed on 7300 Real Time PCR Systems thermocycler (Applied Biosystems) and programmed for 40 cycles at 50 1C for 2 min; 95 1C for 10 min; 95 1C for 15 s and 60 1C for 1 min. To determine hMPV groups, amplified products were sequenced (BigDye; Applied Biosystems) and analyzed using the software SeqMan (DNA-Star; ABI). To assure the quality of the samples concerning the presence of nucleic acids, human hypoxanthine phosphoribosyl transferase (HPRT) control (Pre-developed Taqman Assay Reagents-Human HPRT 20 Â ) was used in all nasal washes according to the manufacturer's instructions (Applied Biosystems). The characteristics of HSCT recipients with hMPV infection are summarized in Table 1 . In two patients, hMPV was detected in NW samples taken during conditioning (cases 5 and 7). Conditioning regimens were BU/CY and BU/melphalan, respectively. Because these infections were diagnosed retrospectively, no intervention was proposed. In one patient (case 7), respiratory hMPV infection in HSCT recipients RR Oliveira et al symptoms persisted for 3 weeks. No severe complication was observed in either case. In 3 of the 11 patients (27.3%), lower respiratory tract infection was diagnosed on the basis of tomographic findings and on the detection of hMPV in BAL. In one patient, RSV pneumonia was diagnosed concurrently. One patient died on day þ 16 owing to graft failure and culturenegative septic shock 6 days after hMPV infection was diagnosed. However, the role of hMPV in the patient's death could not be defined, because influenza B infection was concurrently detected in the sample. hMPV circulated year round, but more frequently during the winter and spring months. The monthly distribution according to year of diagnosis is shown on Figure 2 .
Results
This
Eight of the 11 hMPV-positive samples were sequenced. Both hMPV group A and group B circulated each year. In 2001, two of the three hMPV detected (75%) belonged to group A; in 2002, group A and group B circulated equally; and in 2003, HMPV group A (75%) predominated over group B.
Discussion
Sa˜o Paulo is a subtropical climate megacity with 19 million inhabitants living in the metropolitan area. Although RVs circulate year round, increased frequencies of RV infections can be noted during the fall and winter months. The present study demonstrated a prevalence rate of 7% of hMPV infection in HSCT recipients with upper respiratory symptoms during 3 consecutive years. In a prospective 4-year study, Martino et al. 6 found a 2-year incidence of 5.2 and 3% in allogeneic and autologous HSCT recipients, respectively. In our series, the prevalence rate reached 11% in 2003, probably reflecting greater intensity of hMPV circulation in the community that year. However, nosocomial transmission cannot be discarded. Studies have demonstrated that hMPV cases in transplant patients are clustered in epidemic fashion and that both community or nosocomial transmission may occur. 18 Other respiratory viruses (RSV and parainfluenza virus (PIV)) can also be transmitted among patients, especially in the outpatient setting, where the implementation of strict infection control measures are limited. 17, 19 With regard to disease severity, progression to pneumonia is frequent and has been more frequently reported in allogeneic than in autologous HSCT recipients with hMPV infection. 6, 7 In the present series, 3 of the 11 patients (27.3%) with hMPV infection developed pneumonia. However, we could not establish the role of hMPV in one episode because RSV was also detected in the same BAL sample. Among the 11 HSCT recipients with hMPV hMPV infection in HSCT recipients RR Oliveira et al infection, 1 patient died due to graft failure, culturenegative septic shock and respiratory failure 8 days after hMPV was detected. Because influenza B infection was concurrently detected in that NW sample and post-mortem examination was not performed, the contribution of hMPV to the patient's death could not be established. However, other authors have previously described fatal outcome with similar clinical findings. 6, 7, 18 Human metapneumovirus was circulated year round, but more cases were diagnosed in the winter and spring months as previously observed in other countries 20, 21 and in the pediatric population of the city of Sa˜o Paulo. This alternate pattern of circulation is widely known among other RVs and suggests that hMPV may vary in genetic structure, to allow for a seasonal shift in predominant genotype and the maintenance of infection rates. 23 We conclude that the prevalence rates of hMPV infection in HSCT recipients living in Brazil are similar to those observed in the northern hemisphere. Both genotypes circulate yearly and they are detected more frequently in late winter and spring. Fatal cases of hMPV have been described in HSCT recipients and all efforts should be made to detect hMPV in real time. Sensitive techniques should be included in the diagnostic assessment of HSCT recipients, with symptoms of upper respiratory tract infection, prompting more strict infection control and prevention of nosocomial transmission of hMPV.
